- 14 mg/m2 IV (over 4 hrs) on days 1, 8 and 15 of a 28 day cycle
- Repeat cycles q28 days if patient benefits from and tolerates therapy
- Modification based on toxicity
Peripheral T-cell lymphoma (PTCL)
- 14 mg/m2 IV (over 4 hrs) on days 1, 8 and 15 of a 28 day cycle
- Repeat cycles q28 days if patient benefits from and tolerates therapy
- Modification based on toxicity
- Nonhematological toxicities except alopecia
- Grade 2/3: Delay treatment until toxicity returns to
Grade 1 or baseline, restart at 14 mg/m2. If Grade 3 toxicity recurs, delay treatment until toxicity returns to Grade 1 or baseline then permanently reduce dose to 10 mg/m2 - Grade 4: Delay treatment until toxicity returns to Grade 1 or baseline then permanently reduce dose to 10 mg/m2
- Grade 3 or 4 toxicities recur after dose reduction; discontinue therapy
- Hematologic toxicity
- Grade 3/4 neutropenia/thrombocytopenia: Delay treatment until ANC
1.5 x 10 9/L and/or platelet count 75 x 10 9/L or baseline, then restart at 14 mg/m2 - Grade 4 toxicity (febrile 38.5 C) neutropenia/thrombocytopenia requiring platelet transfusions: Delay treatment until specific cytopenia returns to Grade 1 or baseline, then permanently reduce to 10 mg/m2
- Safety and effectiveness in pediatric patients have not been established
